Antibody therapy of cancer - PubMed (original) (raw)

Review

. 2012 Mar 22;12(4):278-87.

doi: 10.1038/nrc3236.

Affiliations

• PMID: 22437872
• DOI: 10.1038/nrc3236

Review

Antibody therapy of cancer

Andrew M Scott et al. Nat Rev Cancer. 2012.

Abstract

The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.

Trial registration: ClinicalTrials.gov NCT00829166 NCT01120184.

PubMed Disclaimer

Similar articles

• [An overview of antibody-based cancer therapy].
  Miao QF, Shao RG, Zhen YS. Miao QF, et al. Yao Xue Xue Bao. 2012 Oct;47(10):1261-8. Yao Xue Xue Bao. 2012. PMID: 23289136 Review. Chinese.
• Antibody-targeted drugs and drug resistance--challenges and solutions.
  Shefet-Carasso L, Benhar I. Shefet-Carasso L, et al. Drug Resist Updat. 2015 Jan;18:36-46. doi: 10.1016/j.drup.2014.11.001. Epub 2014 Nov 21. Drug Resist Updat. 2015. PMID: 25476546 Review.
• Are targeted therapies really targeted?
  Schilsky RL. Schilsky RL. Clin Adv Hematol Oncol. 2003 Dec;1(12):722-3. Clin Adv Hematol Oncol. 2003. PMID: 16258475 No abstract available.
• Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
  Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J. Nasiri H, et al. J Cell Physiol. 2018 Sep;233(9):6441-6457. doi: 10.1002/jcp.26435. Epub 2018 Mar 25. J Cell Physiol. 2018. PMID: 29319167 Review.
• Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
  Jackson D, Stover D. Jackson D, et al. Pharm Res. 2015 Nov;32(11):3458-69. doi: 10.1007/s11095-014-1536-7. Epub 2014 Oct 23. Pharm Res. 2015. PMID: 25339341 Free PMC article. Review.

Cited by

• Selected anti-tumor vaccines merit a place in multimodal tumor therapies.
  Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlücker E, Meyer-Pittroff R, Ott OJ, Fietkau R, Gaipl US, Frey B. Weiss EM, et al. Front Oncol. 2012 Oct 9;2:132. doi: 10.3389/fonc.2012.00132. eCollection 2012. Front Oncol. 2012. PMID: 23087898 Free PMC article.
• Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence.
  Kim N, Lee ES, Won SE, Yang M, Lee AJ, Shin Y, Ko Y, Pyo J, Park HJ, Kim KW. Kim N, et al. Korean J Radiol. 2022 Nov;23(11):1089-1101. doi: 10.3348/kjr.2022.0225. Epub 2022 Sep 5. Korean J Radiol. 2022. PMID: 36098343 Free PMC article. Review.
• Antibody Drug Conjugates: Nonclinical Safety Considerations.
  Hinrichs MJ, Dixit R. Hinrichs MJ, et al. AAPS J. 2015 Sep;17(5):1055-64. doi: 10.1208/s12248-015-9790-0. Epub 2015 May 30. AAPS J. 2015. PMID: 26024656 Free PMC article. Review.
• The Structural Role of Antibody N-Glycosylation in Receptor Interactions.
  Subedi GP, Barb AW. Subedi GP, et al. Structure. 2015 Sep 1;23(9):1573-1583. doi: 10.1016/j.str.2015.06.015. Epub 2015 Jul 23. Structure. 2015. PMID: 26211613 Free PMC article.
• Recent developments in receptor tyrosine kinases targeted anticancer therapy.
  Raval SH, Singh RD, Joshi DV, Patel HB, Mody SK. Raval SH, et al. Vet World. 2016 Jan;9(1):80-90. doi: 10.14202/vetworld.2016.80-90. Epub 2016 Jan 29. Vet World. 2016. PMID: 27051190 Free PMC article. Review.

References

1. 1. J Natl Cancer Inst. 1991 Jan 16;83(2):97-104 - PubMed
2. 1. Clin Cancer Res. 2007 Sep 1;13(17):5133-43 - PubMed
3. 1. J Clin Oncol. 2003 Nov 1;21(21):3940-7 - PubMed
4. 1. Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4071-6 - PubMed
5. 1. J Clin Oncol. 2005 Mar 1;23(7):1538-47 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database